Share Name Share Symbol Market Type Share ISIN Share Description
Salvarx Group Plc LSE:SALV London Ordinary Share IM00BZ4SS228 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.50 0.00 0.00 0.00 0.00 - 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -0.5 1.0 4.5 2

Salvarx Share Discussion Threads

Showing 151 to 175 of 475 messages
Chat Pages: Latest  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
12/7/2018
09:53
This has mega bag potential though with stakes in private US biotechs
the stigologist
12/7/2018
09:43
bio sector starting to get a bid and outperform i'm adding ; syncona nicely moving bio fund novartis and crispa both mellon tips will move up from here
kristini2
12/7/2018
09:24
Melting up on no news Extraordinary
the stigologist
11/7/2018
15:17
very underowned i guess
the stigologist
11/7/2018
10:09
Post results road show? Liquidity event coming ?
the stigologist
11/7/2018
00:20
Just melting up on the sly
the stigologist
01/7/2018
10:51
Outlook The main objective when we started this Company was to identify drugs/products that had interesting science behind them and that could benefit from our drug development and commercialization expertise. We have now been successful in sourcing a wide range of products from around the globe. Each has specific needs and challenges that our extended team has been focused on resolving. Not everything will go as planned, but the team has many years of experience in overcoming challenges, and finding creative solutions to push the programs forward. The real reward is trying to help give hope to cancer patients for whom the available drugs have failed and are in need of new options. I am reminded of how challenging this is as one of our investigators writes to me about a woman in her 30s with no other options who is eager to get into one of our trials. The investor community is also optimistic about this sector with record amounts of venture money flowing into startups this past year. In fact, in February 2018, BMS recorded the largest upfront payment for a license in history. They paid US$3.6 billion for 35% of the profits on Nektar's immunotherapy after seeing data on approximately 40 patients. At the SalvaRx corporate level, we continue to identify potential investments or acquisitions. We expect to grow further by acquisition, investment or licensing arrangements as we identify novel cancer immunotherapies. Not all of our projects will progress, as we are continually prioritizing those with the highest probability of success. Dr lan Walters Chief Executive Officer 27 June 2018
the stigologist
01/7/2018
10:51
breaking out Golden Cross
the stigologist
27/6/2018
15:20
Amazing....+ almost 14% and all that on really quite small. Heaven only knows what the lift-up will be when the volume is really turned up. 30.6% at the lowest ask on show. Happy days! f
fillipe
05/5/2018
13:38
Satisfactory end to the week.
fig1
03/5/2018
08:15
No liquidity in the shares. Won't take much buying to get the price above 30p where it should be.
wiseacre
02/5/2018
12:46
Patience Fillipe, patience.
fig1
02/5/2018
12:41
SALV + 18% today, although seems to have dropped off the radars of most folks. f
fillipe
09/4/2018
17:21
Aren't immunotherapy related stocks out of favour right now- given some recent failings in the immunotherapy related process and sector ?
kristini2
05/4/2018
16:17
Actually dexdringle I think the stock is grossly undervalued but as far as the company is concerned it appears not to give a button, in terms of promotion here, and I have heard the American CEO, not only has a contempt for AIM, but, is looking to get the shares quoted his side of the Atlantic where biotech gets a better rating. With regard to my comment on the quality of investors I hardly think the promoter of the company at IPO, Peterhouse, has a great roster of long-term investors to get the stock away. Maybe you are one of them! No offence intended.
wiseacre
04/4/2018
14:39
"wiseacre 22 Mar '18 - 11:22 - 111 of 112 The problem is that those who subscribed at 33p, not the highest quality of investor......." Eh ? Why would investing at 33p not been a sign of being a high quality investor ? Presumably you were a genius and were shorting it from there (and are still doing so) thus making you a very high quality investor ? Unless all investors who buy something that goes down are poor quality investors - in which case please stand up the person who only ever buys things that go up !!
dexdringle
22/3/2018
16:41
well they could, but i'm rather disillusioned with riskier and small cap investing I think you;re better off going to a casino
kristini2
22/3/2018
11:22
The problem is that those who subscribed at 33p, not the highest quality of investor, have lost heart and there could be some tax loss selling, not to mention the fact that the shares have fallen on very low volume. I think Kristin's time horizon is far too pessimistic and the shares could easily double in the blink of an eye.
wiseacre
20/3/2018
18:38
It's fairly illiquid with little volumes period, and so one must be prepared to hold long term, i mean maybe 5 years + I am thinking maybe 10 years It will not take too much given the market cap here to see positive price action, and so the risk reward over 5 years looks good. The speculative nature is a given
kristini2
20/3/2018
16:25
Good point. What I don't understand is why the price peaked at 45p and is now 20p (ish). surely there are not sufficient fickle holders to cause the price to fall and fall. Most must be in it for the long haul. So why the volatility ?
dexdringle
20/3/2018
16:20
Come on dexdringle you should know that biotech has long lead times but with cancer immunotherapy lead times are quicker. If you have no patience you shouldn't be here.
wiseacre
19/3/2018
15:01
....if they could be so kind as to see their way, if it isn't too much trouble, to start MAKING SOME IMPRESSIVE PROFITS then I suspect that we all might become a little more 'enchanted'.......
dexdringle
19/3/2018
10:46
The American management is disenchanted with AIM and, I believe, could be looking at a listing their side of the Atlantic
wiseacre
15/3/2018
23:41
Yep I don't think I'd invest just on Mellon The American angle more interesting
the stigologist
15/3/2018
17:42
You are quite right Stig but this one is led by an American who came out of Bristol Myers Squibb, the leaders in immunotherapy, and has done zilch PR for the company. The company was floated at 33p two years ago and has come a long way since then. Time will tell.
wiseacre
Chat Pages: Latest  7  6  5  4  3  2  1
Your Recent History
LSE
SALV
Salvarx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191118 16:13:28